alpha-2 adrenergic agent for treatment of intraocular pressure and eye diseases via intravitreal and intracameral pathways

摘要

alpha-2 adrenergic summary for treatment of intraocular pressure and eye diseases via intravitreal and intracameral pathways The present invention provides a method of reducing intraocular pressure comprising administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5- (2-imidazolin-2-ylamino) benzimidazole, or a salt thereof to the eye of an affected patient, as a single dose, wherein the affected eye has a lower intraocular pressure than the baseline.